Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626968 | 0.88 | HSD17B10 (0.46) | NPC1HSD17B10UCHL1ALDH1A1LMNA | |
| SCHEMBL30439876 | 0.88 | HSD17B10 (0.40) | NPC1HSD17B10UCHL1ALDH1A1LMNA | |
| SCHEMBL4147539 | 0.85 | NPC1 (0.39) | NPC1HSD17B10UCHL1LMNANPSR1 | |
| SCHEMBL4717013 | 0.85 | HSD17B10 (0.44) | NPC1HSD17B10UCHL1ALDH1A1LMNA | |
| SCHEMBL4397346 | 0.84 | NPC1 (0.39) | NPC1HSD17B10UCHL1ALDH1A1LMNA | |
| SCHEMBL31603663 | 0.82 | MEN1 (0.42) | HSD17B10ALDH1A1TSHRHPGDATM | |
| SCHEMBL3805159 | 0.81 | HSD17B10 (0.42) | NPC1HSD17B10UCHL1ALDH1A1LMNA | |
| SCHEMBL4766170 | 0.81 | HSD17B10 (0.42) | NPC1HSD17B10UCHL1ALDH1A1LMNA | |
| SCHEMBL5420095 | 0.78 | HSD17B10 (0.42) | HSD17B10 | |
| SCHEMBL21818930 | 0.78 | ATM (0.42) | NPC1HSD17B10UCHL1ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211926-B2 | Bicyclic pyrazolo-heterocycles | CARA THERAPEUTICS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110275609-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110144121-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7741350-B1 | Bicyclic pyrazolo-heterocycles | CARA THERAPEUTICS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144121-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CNR1, CNR2, TRPV1 | NPC1 450/4885HSD17B10 2235/4885UCHL1 4477/4885 |
| US-20110275609-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CNR1, CNR2, HRH4 | NPC1 1196/4885HSD17B10 3311/4885UCHL1 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.